Attenuated Mycoplasma Bacteria
AssigneesFundació Centre De Regulació GenòMica, Institució Catalana De Recerca I Estudis AvançAts
InventorsCarlos Piñero Lambea, Maria Lluch Senar, Luis Serrano Pubul
Life of this patent
Estimating the term…
Abstract
The present invention concerns genetically modified Mycoplasma bacteria. Also intended are methods of generating attenuated Mycoplasma bacteria and their use to produce heterologous gene products. Further intended are pharmaceutical compositions comprising the attenuated Mycoplasma bacteria described herein.
Claims27
A genetically modified Mycoplasma bacterium, wherein the Mycoplasma bacterium comprises in its genome a deletion, substitution, and/or insertion of one or more nucleotides in the operon of the Ca2+ dependent cytotoxic nuclease gene (MPN133) and the operon of the ADP-ribosyltransferase CARDS gene (MPN372) that reduce the pathogenicity and/or immunogenicity of the Mycoplasma bacterium as compared to a reference Mycoplasma bacterium having an otherwise identical genomic sequence lacking the deletion, substitution, and/or insertion in the operons.
7-14. (canceled)
(canceled)
(canceled)
(canceled)
The genetically modified Mycoplasma bacterium of claim 31, wherein the pharmaceutical composition is a medicament.
The genetically modified Mycoplasma bacterium of claim 31, wherein the pharmaceutical composition is a vaccine.
A method of producing an attenuated Mycoplasma bacterium, wherein the method comprises introducing a deletion, substitution, and/or insertion of one or more nucleotides in at least two genes or operons encoding a gene product independently selected from the group consisting of:
- cytoadherence proteins, lipid synthesis enzymes producing immunogenic products, oxidoreductases, nucleases, toxins, lipoproteins, inflammatory regulating proteins, immunogenic proteins, and cancer inducing proteins.
(canceled)
Dependencies are inferred from the claim text.